Xenogen Corporation has entered into agreements with Bristol-Myers Squibb Company to provide a non-exclusive license for Xenogen's patented real-time imaging technology accompanied by an IVIS Imaging System. Under a separate agreement, Bristol-Myers Squibb will grant Xenogen a non-exclusive license to use Bristol-Myers Squibb's patented Cre Lox Technology.

Bristol-Myers Squibb will be entitled to use Xenogen's real-time, biophotonic imaging technology and Xenogen Bioware in its drug discovery and preclinical drug development research. In return, Bristol-Myers Squibb has granted Xenogen rights to use Cre-Lox technology for its own research, as well as to include it as a commercial service offering in Xenogen's range of custom and production transgenic services.

"By entering into these agreements with Bristol-Myers Squibb, we can mutually expand our research capabilities," said Pamela R. Contag, President of Xenogen Corporation, "The Cre-Lox technology will allow Xenogen to reduce time spent in development and solidify our range of services. In turn, Bristol-Myers Squibb will be able to use our IVIS(r) Imaging System and in vivo biophotonics."

Cre-lox technology can help to streamline research systems and to reduce the laborious traditional procedures of developing individual transgenic models. The Cre-lox method builds more tailored models for human disease, which can ultimately lead to a better understanding of diseases and how to treat them.

Xenogen's real-time biophotonic imaging technology includes the IVIS(r) Imaging System, which is an extremely sensitive camera that allows researchers to monitor and record cellular and genetic activity. Xenogen technology and products are designed to improve experimental data by providing faster and more reliable results in drug research and other research fields.